Resolutions from Annual General Meeting in Abliva AB (publ)
Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva” or the ”Company”) today on May 20, 2022 held its Annual General Meeting (“AGM”). A summary of the resolutions follows.
Press releases
Resolution at the Extraordinary General Meeting in Abliva AB (publ)
Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva” or the ”Company”) has today held an Extraordinary General Meeting. A summary of the resolution follows. The resolution was passed unanimously.
Resolutions from Annual General Meeting in Abliva AB (publ)
Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva” or the ”Company”) today on May 20, 2021 held its Annual General Meeting (“AGM”). Due to the continued spread of the coronavirus and the authorities’ regula ...
Resolutions at the Extraordinary General Meeting in Abliva AB (publ)
Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva” or the ”Company”) has today held an Extraordinary General Meeting. Due to the continued spread of the coronavirus and the authorities’ regulations/advice o ...
Resolutions from Annual General Meeting in NeuroVive Pharmaceutical AB (publ)
NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) today on 20 May 2020 held its Annual General Meeting (AGM). A summary of the resolutions follows.
NeuroVive Pharmaceutical AB (publ): report from EGM
Today, 17 March 2020, an extraordinary general meeting was held in NeuroVive Pharmaceutical AB (publ) (“NeuroVive” or the “Company”). A summary of the resolutions follows. The resolution was passed wi ...
NeuroVive completes recruitment in the second part of its ongoing KL1333 clinical Phase Ia/b study
Lund, Sweden, 20 December 2019, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced the completed recruitment of healthy volunteers in the second part of the company's on ...
NeuroVive announces settlement in dispute with CicloMulsion AG
Lund, Sweden, 16 December 2019, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) announced today that it has fully and finally settled the dispute with CicloMulsion AG regarding certa ...
NeuroVive’s NeuroSTAT project receives FDA Fast Track designation
Lund, Sweden, 27 July 2019, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the company's candidate drug NeuroSTAT, in development for treatment of moderate to s ...
NeuroVive initiates second part of its ongoing KL1333 Phase Ia/b clinical study
Lund, Sweden, 4 July 2019, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the company has initiated the second part in its ongoing Phase Ia/b clinical study wit ...
NeuroVive’s IND for clinical development of NeuroSTAT approved by FDA
Lund, Sweden,10 May 2019, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the US Food and Drug Administration, FDA, has approved NeuroVive's IND (Investigational ...
NeuroVive announces ruling from Supreme Court in case between the company and CicloMulsion AG
Lund, 30 April, 2019- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) announced today that the Supreme Court had delivered its ruling concerning arbitration between NeuroVive and Cic ...